View ValuationEC Healthcare 将来の成長Future 基準チェック /06現在、 EC Healthcareの成長と収益を予測するのに十分なアナリストの調査がありません。主要情報n/a収益成長率n/aEPS成長率Consumer Services 収益成長13.0%収益成長率n/a将来の株主資本利益率n/aアナリストカバレッジNone最終更新日n/a今後の成長に関する最新情報お知らせ • Nov 08Ec Healthcare Provides Sales Expectations for Six Months Ended 30 September 2024EC Healthcare provided sales expectations for Six months ended 30 September 2024. For the six months, The Group expects to record overall Sales Volume of no less than HKD 2,100 million for the Period, representing a decrease of no more than 4% as compared with the same period last year.お知らせ • Aug 16EC Healthcare Provides Group Earnings Guidance for the Period from 1 April 2024 to 30 June 2024EC Healthcare provided group earnings guidance for the period from 1 April 2024 to 30 June 2024. For the quarter, the company expects overall Sales Volume of no less than HKD 1,040 million for the Quarter, representing a decrease of no more than 4% as compared with the same quarter last year.お知らせ • Nov 18Ec Healthcare Provides Earnings Guidance for the Six Months Ended 30 September 2023EC Healthcare provided earnings guidance for the six months ended 30 September 2023. For the period, the company expects a decrease of not more than 80% in profit after tax ("Net Profit") for the Reporting Period as compared with the Net Profit of approximately HKD 105.2 million for the corresponding period ended 30 September 2022. However, if comparing to the second half of financial year ended 31 March 2023, it is expected that the financial results of the Group may record: an increase of not less than 1,000% in Net Profit for the Reporting Period as compared with the Net Profit of approximately HKD 1.8 million for six months ended 31 March 2023. The Board believes that such year-on-year decrease in Net Profit during the Reporting Period was mainly attributable to: the decrease of approximately HKD 43.4 million in subsidies from Hong Kong Government under the Employment Support Scheme; temporary low operation leverage of the newly established service points from the previous financial year ended 31 March 2023; the increase in depreciation and amortization expenses incurred from the organic expansion during the previous financial year ended 31 March 2023; and the increase in interest expenses from bank borrowings of approximately HKD 17.0 million due the increasing interest rate.お知らせ • Jun 20EC Healthcare Provides Unaudited Consolidated Earnings Guidance for the Year Ended 31 March 2023EC Healthcare provided unaudited consolidated earnings guidance for the year ended 31 March 2023. For the year, company expects a decrease of not more than 61% in profit after tax, a decrease of not more than 20% in EBITDA.すべての更新を表示Recent updatesお知らせ • Nov 28EC Healthcare Declares No Dividend for the Six Months Ended September 20, 2025EC Healthcare declared no dividend for the six months ended September 20, 2025 (2024: 1.0 HK Cents).お知らせ • Nov 17EC Healthcare to Report First Half, 2026 Results on Nov 28, 2025EC Healthcare announced that they will report first half, 2026 results on Nov 28, 2025お知らせ • Jun 23EC Healthcare Announces Appointment of Member of the Nomination CommitteeThe board of directors of EC Healthcare announced that Mrs. Leung Yang, Shih Ti Marianne, a non-executive director of the Company and Mr. Ma Ching Nam, an independent non-executive director of the Company, have been appointed as the members of the nomination committee under the Company with effect from 23 June 2025.お知らせ • Jun 19EC Healthcare, Annual General Meeting, Aug 22, 2025EC Healthcare, Annual General Meeting, Aug 22, 2025.お知らせ • Jun 09EC Healthcare to Report Fiscal Year 2025 Results on Jun 19, 2025EC Healthcare announced that they will report fiscal year 2025 results on Jun 19, 2025お知らせ • Nov 28EC Healthcare Declares Ordinary Interim (Semi-Annual) Dividend for the Six Months Ended 30 September 2024, Payable on 24 January 2025EC Healthcare declared Ordinary interim (semi-annual) dividend for the six months ended 30 September 2024 of HKD 0.01 per share. The dividend will be payable on 24 January 2025 with record date of 07 January 2025 and Ex-dividend date of 30 December 2024.お知らせ • Nov 09EC Healthcare to Report First Half, 2025 Results on Nov 28, 2024EC Healthcare announced that they will report first half, 2025 results on Nov 28, 2024お知らせ • Nov 08Ec Healthcare Provides Sales Expectations for Six Months Ended 30 September 2024EC Healthcare provided sales expectations for Six months ended 30 September 2024. For the six months, The Group expects to record overall Sales Volume of no less than HKD 2,100 million for the Period, representing a decrease of no more than 4% as compared with the same period last year.お知らせ • Aug 16EC Healthcare Provides Group Earnings Guidance for the Period from 1 April 2024 to 30 June 2024EC Healthcare provided group earnings guidance for the period from 1 April 2024 to 30 June 2024. For the quarter, the company expects overall Sales Volume of no less than HKD 1,040 million for the Quarter, representing a decrease of no more than 4% as compared with the same quarter last year.お知らせ • Jun 28EC Healthcare, Annual General Meeting, Aug 23, 2024EC Healthcare, Annual General Meeting, Aug 23, 2024.お知らせ • Jun 15EC Healthcare to Report Fiscal Year 2024 Results on Jun 27, 2024EC Healthcare announced that they will report fiscal year 2024 results on Jun 27, 2024お知らせ • Jun 14An undisclosed buyer entered into an agreement to acquire additional 51% stake in Preeminent Medical Centre Limited from EC Healthcare (SEHK:2138) for HKD 80.2 million.An undisclosed buyer entered into an agreement to acquire additional 51% stake in Preeminent Medical Centre Limited from EC Healthcare (SEHK:2138) for HKD 80.2 million on June 12, 2024.お知らせ • Dec 08EC Healthcare Announces the Resignation of Mr. Wong Chi Cheung as Executive Director and Chief Digital Officer of the Company with Effect from 31 December 2023The board of directors of EC Healthcare announced that, Mr. Wong Chi Cheung has tendered his resignation as executive director and chief digital officer of the Company with effect from 31 December 2023 due to other work commitments. Mr. Wong has confirmed that he has no disagreement with the Board and there is no other matter in relation to his resignation that needs to be brought to the attention of The Stock Exchange of Hong Kong Limited or the holders of securities of the Company.お知らせ • Dec 01EC Healthcare Declares an Interim Dividend for the Six Months Ended 30 September 2023, Payable on January 19, 2024EC Healthcare declared an interim dividend of HKD 0.005 per share for the six months ended 30 September 2023. The dividend payable on January 19, 2024 to the shareholders recorded on 05 January 2024 and the Ex-dividend date is 28 December 2023.お知らせ • Nov 18Ec Healthcare Provides Earnings Guidance for the Six Months Ended 30 September 2023EC Healthcare provided earnings guidance for the six months ended 30 September 2023. For the period, the company expects a decrease of not more than 80% in profit after tax ("Net Profit") for the Reporting Period as compared with the Net Profit of approximately HKD 105.2 million for the corresponding period ended 30 September 2022. However, if comparing to the second half of financial year ended 31 March 2023, it is expected that the financial results of the Group may record: an increase of not less than 1,000% in Net Profit for the Reporting Period as compared with the Net Profit of approximately HKD 1.8 million for six months ended 31 March 2023. The Board believes that such year-on-year decrease in Net Profit during the Reporting Period was mainly attributable to: the decrease of approximately HKD 43.4 million in subsidies from Hong Kong Government under the Employment Support Scheme; temporary low operation leverage of the newly established service points from the previous financial year ended 31 March 2023; the increase in depreciation and amortization expenses incurred from the organic expansion during the previous financial year ended 31 March 2023; and the increase in interest expenses from bank borrowings of approximately HKD 17.0 million due the increasing interest rate.お知らせ • Nov 17EC Healthcare to Report First Half, 2024 Results on Nov 30, 2023EC Healthcare announced that they will report first half, 2024 results on Nov 30, 2023お知らせ • Nov 02EC Healthcare Announces Executive ChangesEC Healthcare Announced that Mr. Tang Chi Fai Eddy has resigned as chief executive officer of the Company with effect from 1 November 2023 due to the wish to enable the Company to fully comply with code provision C.2.1 of the Corporate Governance Code of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited, which states that the roles of chairman and chief executive should be separate and should not be performed by the same individual. Mr. Tang has confirmed that he has no disagreement with the Board and there is no matter in relation to his resignation as chief executive officer of the Company that needs to be brought to the attention of The Stock Exchange of Hong Kong Limited or the holders of securities of the Company. Mr. Tang will continue to be the Chairman of the Board and an executive Director. Mr. Lu Lyn Wade Leslie, an executive director and the co-chief executive officer of the Company, is re-designated as the chief executive officer of the Company with effect from 1 November 2023. Mr. Lu, aged 44, joined the Group in August 2021 and is an executive director and was the co-chief executive officer of the Company. He focuses on Group's high level strategy, systems building, implementation and cultural alignment. Mr. Lu is a seasoned corporate executive with 22 years of management experience across multiple industry verticals. Mr. Lu worked in Sun Hung Kai Real Estate Agency Limited as Deputy Chief Digital Officer. Before that, Mr. Lu was an executive at Cathay Pacific Airways Limited during 2001-2007 & 2008-2020. His roles include General Manager Digital, General Manager Product, managerial positions in airline planning, cargo, flight operations, customer relationship management as well as oversea station at Thailand, Vietnam and United States. Mr. Lu graduated from The Hong Kong University of Science and Technology ("HKUST") with a Bachelor's degree in Civil Engineering in 2001 and a master's degree in Global Finance in 2009 from New York University and HKUST. Mr. Lu has entered into a service agreement with the Company on 23 August 2021 as an executive director and the co-chief executive officer of the Company for a term of 3 years commencing on 23 August 2021. A supplemental agreement has been entered into between Mr. Lu and the Company on 1 November 2023, pursuant to which Mr. Lu is re-designated as chief executive officer of the Company. Pursuant to the service agreement (as amended), the remuneration of Mr. Lu shall remain unchanged at HKD 400,000 per month plus other discretionary bonus and share options as may be determined by the Board and other terms of appointment shall also remain unchanged. His remuneration package is determined by the Board based on the recommendation of the remuneration committee of the Company, taking into account the salaries paid by comparable companies, time commitment, duties and responsibilities of Mr. Lu, the Company's performance and profitability, the remuneration policy and prevailing market rate. As at the date of this announcement, Mr. Lu holds 10,000,000 share options in the Company.お知らせ • Sep 02Ec Healthcare Approves Dividend for the Year Ended 31 March 2023, Payment Date Is 18 September 2023EC Healthcare on 23 August 2023 approved dividend of HKD 0.042 per share for the year ended 31 March 2023. Record date is 05 September 2023. Payment date is 18 September 2023. Ex-dividend date is 04 September 2023.お知らせ • Aug 24Ec Healthcare Approves Final Dividend for the Year Ended 31 March 2023EC Healthcare at its annual general meeting held on 23 August 2023 approved final dividend of HKD 0.042 per share for the year ended 31 March 2023.お知らせ • Jun 24+ 1 more updateEC Healthcare, Annual General Meeting, Aug 23, 2023EC Healthcare, Annual General Meeting, Aug 23, 2023.お知らせ • Jun 20EC Healthcare Provides Unaudited Consolidated Earnings Guidance for the Year Ended 31 March 2023EC Healthcare provided unaudited consolidated earnings guidance for the year ended 31 March 2023. For the year, company expects a decrease of not more than 61% in profit after tax, a decrease of not more than 20% in EBITDA.お知らせ • Jun 13EC Healthcare to Report Fiscal Year 2023 Final Results on Jun 23, 2023EC Healthcare announced that they will report fiscal year 2023 final results on Jun 23, 2023 このセクションでは通常、投資家が会社の利益創出能力を理解する一助となるよう、プロのアナリストのコンセンサス予想に基づく収益と利益の成長予測を提示する。しかし、EC Healthcare は十分な過去のデータを提供しておらず、アナリストの予測もないため、過去のデータを外挿したり、アナリストの予測を使用しても、その将来の収益を確実に算出することはできません。 シンプリー・ウォール・ストリートがカバーする企業の97%は過去の財務データを持っているため、これはかなり稀な状況です。 業績と収益の成長予測OTCPK:UNHL.F - アナリストの将来予測と過去の財務データ ( )HKD Millions日付収益収益フリー・キャッシュフロー営業活動によるキャッシュ平均アナリスト数3/31/20254,140-167686743N/A12/31/20244,146-89659768N/A9/30/20244,153-12632793N/A6/30/20244,182-15580741N/A3/31/20244,211-19528689N/A12/31/20234,157-11422709N/A9/30/20234,104-4317729N/A6/30/20233,98933255667N/A3/31/20233,87570193605N/A12/31/20223,62293162499N/A9/30/20223,369117132392N/A6/30/20223,144157240500N/A3/31/20222,920198348608N/A12/31/20212,823253479684N/A9/30/20212,727309610760N/A6/30/20212,404251541690N/A3/31/20212,080193472621N/A12/31/20201,854163487597N/A9/30/20201,627133503573N/A6/30/20201,788210505574N/A3/31/20201,949287507576N/A12/31/20192,023325273452N/A9/30/20192,09836440327N/A6/30/20191,975363-5283N/A3/31/20191,852361-49238N/A12/31/20181,715355N/A278N/A9/30/20181,578348N/A317N/A6/30/20181,450314N/A320N/A3/31/20181,322279N/A324N/A12/31/20171,253266N/A302N/A9/30/20171,183253N/A280N/A6/30/20171,079227N/A230N/A3/31/2017975201N/A180N/A12/31/2016878170N/A123N/A9/30/2016780139N/A66N/A6/30/2016744144N/A71N/A3/31/2016708149N/A76N/A12/31/2015688166N/A105N/A9/30/2015668183N/A134N/A6/30/2015645179N/A146N/A3/31/2015621174N/A159N/Aもっと見るアナリストによる今後の成長予測収入対貯蓄率: UNHL.Fの予測収益成長が 貯蓄率 ( 3.3% ) を上回っているかどうかを判断するにはデータが不十分です。収益対市場: UNHL.Fの収益がUS市場よりも速く成長すると予測されるかどうかを判断するにはデータが不十分です高成長収益: UNHL.Fの収益が今後 3 年間で 大幅に 増加すると予想されるかどうかを判断するにはデータが不十分です。収益対市場: UNHL.Fの収益がUS市場よりも速く成長すると予測されるかどうかを判断するにはデータが不十分です。高い収益成長: UNHL.Fの収益が年間20%よりも速く成長すると予測されるかどうかを判断するにはデータが不十分です。一株当たり利益成長率予想将来の株主資本利益率将来のROE: UNHL.Fの 自己資本利益率 が 3 年後に高くなると予測されるかどうかを判断するにはデータが不十分です成長企業の発掘7D1Y7D1Y7D1YConsumer-services 業界の高成長企業。View Past Performance企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2025/11/11 10:45終値2025/08/14 00:00収益2025/03/31年間収益2025/03/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレーク本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋EC Healthcare 0 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。7 アナリスト機関Zhuonan XuChina International Capital Corporation Limitednull nullChina International Capital Corporation Limitednull nullCMB International Securities Limited4 その他のアナリストを表示
お知らせ • Nov 08Ec Healthcare Provides Sales Expectations for Six Months Ended 30 September 2024EC Healthcare provided sales expectations for Six months ended 30 September 2024. For the six months, The Group expects to record overall Sales Volume of no less than HKD 2,100 million for the Period, representing a decrease of no more than 4% as compared with the same period last year.
お知らせ • Aug 16EC Healthcare Provides Group Earnings Guidance for the Period from 1 April 2024 to 30 June 2024EC Healthcare provided group earnings guidance for the period from 1 April 2024 to 30 June 2024. For the quarter, the company expects overall Sales Volume of no less than HKD 1,040 million for the Quarter, representing a decrease of no more than 4% as compared with the same quarter last year.
お知らせ • Nov 18Ec Healthcare Provides Earnings Guidance for the Six Months Ended 30 September 2023EC Healthcare provided earnings guidance for the six months ended 30 September 2023. For the period, the company expects a decrease of not more than 80% in profit after tax ("Net Profit") for the Reporting Period as compared with the Net Profit of approximately HKD 105.2 million for the corresponding period ended 30 September 2022. However, if comparing to the second half of financial year ended 31 March 2023, it is expected that the financial results of the Group may record: an increase of not less than 1,000% in Net Profit for the Reporting Period as compared with the Net Profit of approximately HKD 1.8 million for six months ended 31 March 2023. The Board believes that such year-on-year decrease in Net Profit during the Reporting Period was mainly attributable to: the decrease of approximately HKD 43.4 million in subsidies from Hong Kong Government under the Employment Support Scheme; temporary low operation leverage of the newly established service points from the previous financial year ended 31 March 2023; the increase in depreciation and amortization expenses incurred from the organic expansion during the previous financial year ended 31 March 2023; and the increase in interest expenses from bank borrowings of approximately HKD 17.0 million due the increasing interest rate.
お知らせ • Jun 20EC Healthcare Provides Unaudited Consolidated Earnings Guidance for the Year Ended 31 March 2023EC Healthcare provided unaudited consolidated earnings guidance for the year ended 31 March 2023. For the year, company expects a decrease of not more than 61% in profit after tax, a decrease of not more than 20% in EBITDA.
お知らせ • Nov 28EC Healthcare Declares No Dividend for the Six Months Ended September 20, 2025EC Healthcare declared no dividend for the six months ended September 20, 2025 (2024: 1.0 HK Cents).
お知らせ • Nov 17EC Healthcare to Report First Half, 2026 Results on Nov 28, 2025EC Healthcare announced that they will report first half, 2026 results on Nov 28, 2025
お知らせ • Jun 23EC Healthcare Announces Appointment of Member of the Nomination CommitteeThe board of directors of EC Healthcare announced that Mrs. Leung Yang, Shih Ti Marianne, a non-executive director of the Company and Mr. Ma Ching Nam, an independent non-executive director of the Company, have been appointed as the members of the nomination committee under the Company with effect from 23 June 2025.
お知らせ • Jun 19EC Healthcare, Annual General Meeting, Aug 22, 2025EC Healthcare, Annual General Meeting, Aug 22, 2025.
お知らせ • Jun 09EC Healthcare to Report Fiscal Year 2025 Results on Jun 19, 2025EC Healthcare announced that they will report fiscal year 2025 results on Jun 19, 2025
お知らせ • Nov 28EC Healthcare Declares Ordinary Interim (Semi-Annual) Dividend for the Six Months Ended 30 September 2024, Payable on 24 January 2025EC Healthcare declared Ordinary interim (semi-annual) dividend for the six months ended 30 September 2024 of HKD 0.01 per share. The dividend will be payable on 24 January 2025 with record date of 07 January 2025 and Ex-dividend date of 30 December 2024.
お知らせ • Nov 09EC Healthcare to Report First Half, 2025 Results on Nov 28, 2024EC Healthcare announced that they will report first half, 2025 results on Nov 28, 2024
お知らせ • Nov 08Ec Healthcare Provides Sales Expectations for Six Months Ended 30 September 2024EC Healthcare provided sales expectations for Six months ended 30 September 2024. For the six months, The Group expects to record overall Sales Volume of no less than HKD 2,100 million for the Period, representing a decrease of no more than 4% as compared with the same period last year.
お知らせ • Aug 16EC Healthcare Provides Group Earnings Guidance for the Period from 1 April 2024 to 30 June 2024EC Healthcare provided group earnings guidance for the period from 1 April 2024 to 30 June 2024. For the quarter, the company expects overall Sales Volume of no less than HKD 1,040 million for the Quarter, representing a decrease of no more than 4% as compared with the same quarter last year.
お知らせ • Jun 28EC Healthcare, Annual General Meeting, Aug 23, 2024EC Healthcare, Annual General Meeting, Aug 23, 2024.
お知らせ • Jun 15EC Healthcare to Report Fiscal Year 2024 Results on Jun 27, 2024EC Healthcare announced that they will report fiscal year 2024 results on Jun 27, 2024
お知らせ • Jun 14An undisclosed buyer entered into an agreement to acquire additional 51% stake in Preeminent Medical Centre Limited from EC Healthcare (SEHK:2138) for HKD 80.2 million.An undisclosed buyer entered into an agreement to acquire additional 51% stake in Preeminent Medical Centre Limited from EC Healthcare (SEHK:2138) for HKD 80.2 million on June 12, 2024.
お知らせ • Dec 08EC Healthcare Announces the Resignation of Mr. Wong Chi Cheung as Executive Director and Chief Digital Officer of the Company with Effect from 31 December 2023The board of directors of EC Healthcare announced that, Mr. Wong Chi Cheung has tendered his resignation as executive director and chief digital officer of the Company with effect from 31 December 2023 due to other work commitments. Mr. Wong has confirmed that he has no disagreement with the Board and there is no other matter in relation to his resignation that needs to be brought to the attention of The Stock Exchange of Hong Kong Limited or the holders of securities of the Company.
お知らせ • Dec 01EC Healthcare Declares an Interim Dividend for the Six Months Ended 30 September 2023, Payable on January 19, 2024EC Healthcare declared an interim dividend of HKD 0.005 per share for the six months ended 30 September 2023. The dividend payable on January 19, 2024 to the shareholders recorded on 05 January 2024 and the Ex-dividend date is 28 December 2023.
お知らせ • Nov 18Ec Healthcare Provides Earnings Guidance for the Six Months Ended 30 September 2023EC Healthcare provided earnings guidance for the six months ended 30 September 2023. For the period, the company expects a decrease of not more than 80% in profit after tax ("Net Profit") for the Reporting Period as compared with the Net Profit of approximately HKD 105.2 million for the corresponding period ended 30 September 2022. However, if comparing to the second half of financial year ended 31 March 2023, it is expected that the financial results of the Group may record: an increase of not less than 1,000% in Net Profit for the Reporting Period as compared with the Net Profit of approximately HKD 1.8 million for six months ended 31 March 2023. The Board believes that such year-on-year decrease in Net Profit during the Reporting Period was mainly attributable to: the decrease of approximately HKD 43.4 million in subsidies from Hong Kong Government under the Employment Support Scheme; temporary low operation leverage of the newly established service points from the previous financial year ended 31 March 2023; the increase in depreciation and amortization expenses incurred from the organic expansion during the previous financial year ended 31 March 2023; and the increase in interest expenses from bank borrowings of approximately HKD 17.0 million due the increasing interest rate.
お知らせ • Nov 17EC Healthcare to Report First Half, 2024 Results on Nov 30, 2023EC Healthcare announced that they will report first half, 2024 results on Nov 30, 2023
お知らせ • Nov 02EC Healthcare Announces Executive ChangesEC Healthcare Announced that Mr. Tang Chi Fai Eddy has resigned as chief executive officer of the Company with effect from 1 November 2023 due to the wish to enable the Company to fully comply with code provision C.2.1 of the Corporate Governance Code of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited, which states that the roles of chairman and chief executive should be separate and should not be performed by the same individual. Mr. Tang has confirmed that he has no disagreement with the Board and there is no matter in relation to his resignation as chief executive officer of the Company that needs to be brought to the attention of The Stock Exchange of Hong Kong Limited or the holders of securities of the Company. Mr. Tang will continue to be the Chairman of the Board and an executive Director. Mr. Lu Lyn Wade Leslie, an executive director and the co-chief executive officer of the Company, is re-designated as the chief executive officer of the Company with effect from 1 November 2023. Mr. Lu, aged 44, joined the Group in August 2021 and is an executive director and was the co-chief executive officer of the Company. He focuses on Group's high level strategy, systems building, implementation and cultural alignment. Mr. Lu is a seasoned corporate executive with 22 years of management experience across multiple industry verticals. Mr. Lu worked in Sun Hung Kai Real Estate Agency Limited as Deputy Chief Digital Officer. Before that, Mr. Lu was an executive at Cathay Pacific Airways Limited during 2001-2007 & 2008-2020. His roles include General Manager Digital, General Manager Product, managerial positions in airline planning, cargo, flight operations, customer relationship management as well as oversea station at Thailand, Vietnam and United States. Mr. Lu graduated from The Hong Kong University of Science and Technology ("HKUST") with a Bachelor's degree in Civil Engineering in 2001 and a master's degree in Global Finance in 2009 from New York University and HKUST. Mr. Lu has entered into a service agreement with the Company on 23 August 2021 as an executive director and the co-chief executive officer of the Company for a term of 3 years commencing on 23 August 2021. A supplemental agreement has been entered into between Mr. Lu and the Company on 1 November 2023, pursuant to which Mr. Lu is re-designated as chief executive officer of the Company. Pursuant to the service agreement (as amended), the remuneration of Mr. Lu shall remain unchanged at HKD 400,000 per month plus other discretionary bonus and share options as may be determined by the Board and other terms of appointment shall also remain unchanged. His remuneration package is determined by the Board based on the recommendation of the remuneration committee of the Company, taking into account the salaries paid by comparable companies, time commitment, duties and responsibilities of Mr. Lu, the Company's performance and profitability, the remuneration policy and prevailing market rate. As at the date of this announcement, Mr. Lu holds 10,000,000 share options in the Company.
お知らせ • Sep 02Ec Healthcare Approves Dividend for the Year Ended 31 March 2023, Payment Date Is 18 September 2023EC Healthcare on 23 August 2023 approved dividend of HKD 0.042 per share for the year ended 31 March 2023. Record date is 05 September 2023. Payment date is 18 September 2023. Ex-dividend date is 04 September 2023.
お知らせ • Aug 24Ec Healthcare Approves Final Dividend for the Year Ended 31 March 2023EC Healthcare at its annual general meeting held on 23 August 2023 approved final dividend of HKD 0.042 per share for the year ended 31 March 2023.
お知らせ • Jun 24+ 1 more updateEC Healthcare, Annual General Meeting, Aug 23, 2023EC Healthcare, Annual General Meeting, Aug 23, 2023.
お知らせ • Jun 20EC Healthcare Provides Unaudited Consolidated Earnings Guidance for the Year Ended 31 March 2023EC Healthcare provided unaudited consolidated earnings guidance for the year ended 31 March 2023. For the year, company expects a decrease of not more than 61% in profit after tax, a decrease of not more than 20% in EBITDA.
お知らせ • Jun 13EC Healthcare to Report Fiscal Year 2023 Final Results on Jun 23, 2023EC Healthcare announced that they will report fiscal year 2023 final results on Jun 23, 2023